The Impact of Tofacitinib on Quality of Life in Patients with Moderate-to-Severe Psoriasis- An Observational Study.

Indian J Dermatol · 2023 · PMC10389145 · PMID 37529464

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

There was a highly significant reduction in PASI score after 12 weeks of therapy with Tofacitinib (p-value 0.0001) [ Table 1 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.